SCHEMBL2720045

SCHEMBL2720045

Cc1ccc(C(=O)c2cc[nH]c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.64
LMNA P02545 2/20 0.64
SRD5A2 P31213 2/20 0.55
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
CES2 O00748 2/20 0.46
CES1 P23141 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
AKR1C3 P42330 1/20 0.43
HTT P42858 3/20 0.42
PKM P14618 2/20 0.42
ATM Q13315 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
HPGD P15428 1/20 0.42
NLRP1 Q9C000 1/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 1/20 0.42
NTSR1 P30989 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10699004 0.82 LMNA (0.62) ALDH1A1LMNASRD5A2RAB9ANPC1
SCHEMBL52200 0.80 ALDH1A1 (1.00) ALDH1A1LMNASRD5A2RAB9ACES2
SCHEMBL822185 0.80 ALDH1A1 (1.00) ALDH1A1LMNASRD5A2RAB9ACES2
SCHEMBL24186223 0.80 LTA4H (0.52) ALDH1A1LMNARAB9ANPC1CES2
SCHEMBL24186221 0.79 NPSR1 (0.58) ALDH1A1LMNARAB9ANPC1CES2
SCHEMBL14143387 0.79 ALDH1A1 (0.50) ALDH1A1LMNASRD5A2RAB9ANPC1
SCHEMBL4516770 0.79 ALDH1A1 (0.61) ALDH1A1LMNASRD5A2RAB9ANPC1
SCHEMBL11528213 0.78 ALDH1A1 (0.94) ALDH1A1LMNASRD5A2RAB9ACES2
Hydrochloric Acid SCHEMBL27909743 0.78 ALDH1A1 (0.94) ALDH1A1LMNASRD5A2RAB9ACES2
SCHEMBL15662997 0.77 ALDH1A1 (0.65) ALDH1A1LMNASRD5A2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10930926-B2 Nonaqueous electrolyte secondary battery and cathode sheet therefor NITTO DENKO CORPORATION (JP) 2021-02-23 US disclosed
CN-105958011-B Nonaqueous electrolyte secondary battery and positive electrode sheet for same 日东电工株式会社 2020-07-03 CN disclosed
US-20170317345-A1 NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CATHODE SHEET THEREFOR NITTO DENKO CORPORATION (JP) 2017-11-02 US disclosed
US-9735423-B2 Nonaqueous electrolyte secondary battery and cathode sheet therefor NITTO DENKO CORPORATION (JP) 2017-08-15 US disclosed
EP-3057170-B1 NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CATHODE SHEET THEREFOR NITTO DENKO CORP (JP) 2017-04-26 EP disclosed
EP-3057170-A1 NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CATHODE SHEET THEREFOR Nitto Denko Corporation (JP) 2016-08-17 EP disclosed
EP-2728659-B1 NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY AND POSITIVE-ELECTRODE SHEET THEREFOR NITTO DENKO CORP (JP) 2016-02-24 EP disclosed
US-20140220438-A1 NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CATHODE SHEET THEREFOR NITTO DENKO CORPORATION (JP) 2014-08-07 US disclosed
EP-2728659-A1 NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY AND POSITIVE-ELECTRODE SHEET THEREFOR Nitto Denko Corporation (JP) 2014-05-07 EP disclosed
EP-1647546-B1 NOVEL HETEROARYL DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2012-05-02 EP disclosed
EP-1837329-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2007-09-26 EP disclosed
US-7220773-B2 Heterocylic amines used as antidiabetic or hyperglycemic agents DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-22 US disclosed
US-7220773-B2 Heterocylic amines used as antidiabetic or hyperglycemic agents DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-22 US disclosed
US-7220773-B2 Heterocylic amines used as antidiabetic or hyperglycemic agents DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-22 US disclosed
US-20060194857-A1 Novel heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) 2006-08-31 US disclosed
EP-1647546-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-04-19 EP disclosed
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 US disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 US disclosed
US-20040162331-A1 Pyrrole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-08-19 US disclosed
EP-1386913-A1 PYRROLE DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 ALDH1A1 476/4885LMNA 4536/4885SRD5A2 371/4885
US-20060194857-A1 Novel heteroaryl derivative NR0B1, UGT1A10, NR0B2 ALDH1A1 552/4885LMNA 3906/4885SRD5A2 43/4885
US-20040162331-A1 Pyrrole derivative SLC5A1, GLP1R, SLC5A2 ALDH1A1 548/4885LMNA 4783/4885SRD5A2 164/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 ALDH1A1 530/4885LMNA 4564/4885SRD5A2 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.